Dawnzera (autoinjector) is a drug owned by Ionis Pharmaceuticals Inc. It is protected by 5 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 01, 2035. Details of Dawnzera (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10294477 | Compositions And Methods For Modulating Pkk Expression |
May, 2035
(9 years from now) | Active |
| US9670492 | Modulation Of Prekallikrein (Pkk) Expression |
Aug, 2034
(8 years from now) | Active |
| US9127276 | Conjugated antisense compounds and their use |
May, 2034
(8 years from now) | Active |
| US9181549 | Conjugated antisense compounds and their use |
May, 2034
(8 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9315811 | Methods For Modulating Kallikrein (Klkb1) Expression |
Oct, 2032
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Dawnzera (autoinjector)'s patents.
Latest Legal Activities on Dawnzera (autoinjector)'s Patents
Given below is the list of recent legal activities going on the following patents of Dawnzera (autoinjector).
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) | 02 Sep, 2025 | US9315811 |
| Email Notification | 02 Sep, 2025 | US9315811 |
| Email Notification | 21 Mar, 2025 | US9670492 |
| Change in Power of Attorney (May Include Associate POA) | 21 Mar, 2025 | US9670492 |
| Email Notification | 21 Mar, 2025 | US10294477 |
| Change in Power of Attorney (May Include Associate POA) | 21 Mar, 2025 | US10294477 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Nov, 2024 | US9670492 |
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US9127276 |
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US9181549 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Oct, 2023 | US9315811 |
US patents provide insights into the exclusivity only within the United States, but
Dawnzera (autoinjector) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Dawnzera (autoinjector)'s family patents as well as insights into
ongoing legal events
on those patents.
Dawnzera (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dawnzera (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be May 01, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dawnzera (autoinjector) Generics:
There are no approved generic versions for Dawnzera (autoinjector) as of now.
Alternative Brands for Dawnzera (autoinjector)
There are several other brand drugs in the same treatment category as Dawnzera (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Biocryst |
| |||
About Dawnzera (autoinjector)
Dawnzera (Autoinjector) is a drug owned by Ionis Pharmaceuticals Inc. Dawnzera (Autoinjector) uses Donidalorsen Sodium as an active ingredient. Dawnzera (Autoinjector) was launched by Ionis in 2025.
Approval Date:
Dawnzera (autoinjector) was approved by FDA for market use on 21 August, 2025.
Active Ingredient:
Dawnzera (autoinjector) uses Donidalorsen Sodium as the active ingredient. Check out other Drugs and Companies using Donidalorsen Sodium ingredient
Dosage:
Dawnzera (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | SOLUTION | Prescription | SUBCUTANEOUS |